In previous a study, we had developed a novel thermosensitive magnetic delivery system based on liposomes. This study aimed to evaluate the efficiency of this system for the co-delivery of both drugs and genes to the same cell and its anti-tumor effects on gastric cancer. Doxorubicin (DOX) and SATB1 shRNA vector were loaded into the co-delivery system, and in vitro DOX thermosensitive release activity, targeted gene silencing efficiency, targeted cellular uptake, in vitro cytotoxicity, as well as in vivo anti-tumor activity were determined. The results showed that this co-delivery system had desirable targeted delivery efficacy, DOX thermosensitive release and SATB1 gene silencing. Moreover, the co-delivery of DOX and SATB1 shRNA exhibited enhanced activity to inhibit gastric cancer cell growth in vitro and in vivo, compared to single delivery. In conclusion, the novel thermosensitive magnetic drug and gene co-delivery system has promising application in combined chemotherapy and gene therapy for gastric cancer.
References
[1]
Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics. CA Cancer J Clin 58: 71–96. doi: 10.3322/ca.2007.0010
[2]
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893–917. doi: 10.1002/ijc.25516
[3]
Takahashi T, Saikawa Y, Kitagawa Y (2013) Gastric cancer: current status of diagnosis and treatment. Cancers (Basel) 5: 48–63. doi: 10.3390/cancers5010048
[4]
Zhu X, Li J (2010) Gastric carcinoma in China: Current status and future perspectives (Review). Oncol Lett 1: 407–412. doi: 10.3892/ol_00000071
[5]
Yang L (2006) Incidence and mortality of gastric cancer in China. World J Gastroenterol 12: 17–20.
[6]
Alberts SR, Cervantes A, van de Velde CJ (2003) Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2: 31–36.
[7]
Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, et al. (2005) Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 241: 27–39.
[8]
Skeel RT, Khleif SN (2011) Handbook of Cancer Chemotherapy edited by Lippincott Williams and Wilkins, Philadelphia.
[9]
Park SC, Chun HJ (2013) Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver 7: 385–93. doi: 10.5009/gnl.2013.7.4.385
[10]
Kohwi-Shigematsu T, Poterlowicz K, Ordinario E, Han HJ, Botchkarev VA, et al. (2013) Genome organizing function of SATB1 in tumor progression. Semin Cancer Biol 23: 72–9. doi: 10.1016/j.semcancer.2012.06.009
[11]
Patani N, Jiang W, Mansel R, Newbold R, Mokbel K (2009) The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int 9: 18–27. doi: 10.1186/1475-2867-9-18
[12]
Zhou LY, Liu F, Tong J, Chen QQ, Zhang FW (2009) Expression of special AT-rich sequence-binding protein mRNA and its clinicopathological significance in non-small cell lung cancer. J South Med Univ 29: 534–537.
[13]
Agrelo R, Souabni A, Novatchkova M, Haslinger C, Kenner L, et al. (2009) SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells. Dev Cell 16: 507–516. doi: 10.1016/j.devcel.2009.03.006
[14]
Cheng C, Lu X, Wang G, Zheng L, Shu X, et al. (2010) Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS 118: 855–863. doi: 10.1111/j.1600-0463.2010.02673.x
[15]
Lu X, Cheng C, Zhu S, Yang Y, Zheng L, et al. (2010) SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Oncol Rep 24: 981–987. doi: 10.3892/or_00000945
[16]
Zhang J, Zhang B, Zhang X, Sun Y, Wei X, et al. (2013) SATB1 expression is associated with biologic behavior in colorectal carcinoma in vitro and in vivo. PLoS One 8: e47902. doi: 10.1371/journal.pone.0047902
[17]
Huang B, Zhou H, Wang X, Liu Z (2013) Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells. Cancer Cell Int 13: 8. doi: 10.1186/1475-2867-13-8
[18]
Pradhan P, Banerjee R, Bahadur D, Koch C, Mykhaylyk O, et al. (2010) Targeted magnetic liposomes loaded with doxorubicin. Methods Mol Biol 605: 279–293. doi: 10.1007/978-1-60327-360-2_19
[19]
Li W, Liu TS, Sun YH, Shen KT, Shen ZB, et al. (2011) Adjuvant chemotherapy for gastric cancer: more drugs do not mean better efficacy Zhonghua Wei Chang Wai Ke Za Zhi. 14: 432–435.
[20]
Xiao Y, Jaskula-Sztul R, Javadi A, Xu W, Eide J, et al. (2012) Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale 4: 7185–7193. doi: 10.1039/c2nr31853a
[21]
Shim G, Han SE, Yu YH, Lee S, Lee HY, et al. (2011) Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J Control Release 155: 60–66. doi: 10.1016/j.jconrel.2010.10.017
[22]
Shen J, Yin Q, Chen L, Zhang Z, Li Y (2012) Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 33: 8613–8624. doi: 10.1016/j.biomaterials.2012.08.007
[23]
Chen Y, Bathula SR, Li J, Huang L (2010) Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 285: 22639–22650. doi: 10.1074/jbc.m110.125906
[24]
Liu C, Liu F, Feng L, Li M, Zhang J, et al. (2013) The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles. Biomaterials 34: 2547–2564. doi: 10.1016/j.biomaterials.2012.12.038
[25]
Zhao F, Yin H, Li J (2014) Supramolecular self-assembly forming a multifunctional synergistic system for targeted co-delivery of gene and drug. Biomaterials 35: 1050–1062. doi: 10.1016/j.biomaterials.2013.10.044
[26]
Juergen S, Ronald AS, Michael JR (2012) Fundamentals and Applications of Controlled Release Drug Delivery. Springer-Verlag New York Inc press. p291
[27]
Torchilin VP (2010) Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 197: 3–53. doi: 10.1007/978-3-642-00477-3_1
[28]
Heger Z, Cernei N, Kudr J, Gumulec J, Blazkova I, et al. (2013) A novel insight into the cardiotoxicity of antineoplastic drug Doxorubicin. Int J Mol Sci 14: 21629–21646. doi: 10.3390/ijms141121629
[29]
Stebbing J, Gaya A (2002) Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer. Cancer Treat Rev 28: 121–125. doi: 10.1053/ctrv.2002.0262
[30]
Mir R, Pradhan SJ, Galande S (2012) Chromatin organizer SATB1 as a novel molecular target for cancer therapy. Curr Drug Targets 13: 1603–1615. doi: 10.2174/138945012803530008
Chen J, Cheng D, Li J, Wang Y, Guo JX, et al. (2013) Influence of lipid composition on the phase transition temperature of liposomes composed of both DPPC and HSPC. Drug Dev Ind Pharm 39: 197–204. doi: 10.3109/03639045.2012.668912
[33]
Ta T, Porter TM (2013) Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J Control Release 169: 112–25. doi: 10.1016/j.jconrel.2013.03.036
[34]
Gaber MH, Hong K, Huang SK, Papahadjopoulos D (1995) Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma. Pharm Res 12: 1407–16.
[35]
Pradhan P, Giri J, Rieken F, Koch C, Mykhaylyk O, et al. (2010) Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release 142: 108–121. doi: 10.1016/j.jconrel.2009.10.002
[36]
Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, et al. (2000) Locoregional cancer treatment with magnetic drug targeting. Cancer Res 60: 6641–6648.
[37]
Mykhaylyk O, Sánchez-Antequera Y, Vlaskou D, Hammerschmid E, Anton M, et al. (2010) Liposomal magnetofection. Methods Mol Biol 605: 487–525. doi: 10.1007/978-1-60327-360-2_34
[38]
Zheng X, Lu J, Deng L, Xiong Y, Chen J (2009) Preparation and characterization of magnetic cationic liposome in gene delivery. Int J Pharm 366: 211–217. doi: 10.1016/j.ijpharm.2008.09.019
[39]
Wang C, Ding C, Kong M, Dong A, Qian J, et al. (2011) Tumor-targeting magnetic lipoplex delivery of short hairpin RNA suppresses IGF-1R overexpression of lung adenocarcinoma A549 cells in vitro and in vivo. Biochem Biophys Res Commun 410: 537–542. doi: 10.1016/j.bbrc.2011.06.019
